Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 16, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 550,000 Ordinary Shares of 25 pence each.
- Purchase Date: October 16, 2012.
- Price Range: Highest price paid was 1,445 pence per share; lowest price paid was 1,431.5 pence per share.
- Treasury Holdings (Settled): 506,310,427 shares (9.30% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,140,427 shares (10.29% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,938,824,042 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 550,000 shares, which were intended to be held in Treasury. This transaction increased the proportion of shares held in Treasury relative to total voting rights to 10.29% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (506,310,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,938,824,042 shares in issue) for disclosure threshold assessments.
- Check the settlement status of the 550,000 shares purchased on October 16, 2012, to reconcile the difference between settled and unsettled treasury holdings.